This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Other hereditary or degenerative neurological diso...
  • /
  • Assessing The Real-World Hospital Economic Burden ...

Assessing The Real-World Hospital Economic Burden Of Spinal Muscular Atrophy (SMA) In France

Read time: 1 mins
Published:1st Oct 2017
Author: Tetafort A, Couray-Targe S, Harmand S, Ansolabehere X, Maurel F, Hammes F.
Source: Value in Health
Availability: Pay for access, or by subscription
Ref.:Value Health. 2017;20(9):A553

Objectives: To assess the hospital economic burden of SMA for patients with Infantile and other inherited SMA in France.

Methods: The PMSI (Programme de Médicalisation des Systèmes d’Information), a comprehensive national database of French hospital stays, was used to identify SMA patients in 2014 and 2015 with ICD-10 codes: G120 for infantile spinal muscular atrophy, Type I and G121 for other inherited SMA. Patients’ annual costs in acute care, home hospitalizations and rehabilitation care were estimated during the 2015 year, according to the National Health Insurance (NHI) perspective using respective Diagnosis Related Groups (DRGs) and corresponding tariffs (€2016).

Results: 183 patients with infantile SMA and 732 with other inherited SMA were identified. At identification time, the median age was 3 years, ranging from 0 to 19 for infantile SMA patients, and 21 years, ranging from 0 to 85 for other inherited SMA patients. Both populations were mainly managed with acute care and most frequently for nervous system or respiratory issues. Based on hospital stays observed in 2015, the overall annual cost of hospitalization was estimated at €1.8 million for patients with infantile SMA and €5.3 million for patients with other inherited SMA. The average hospital cost for infantile SMA patient was €13,400, ranging from €226 to €111,200. 48% of this cost was due to acute care, 45% to rehabilitation care and 7% to home stays. For other inherited SMA patients, the average hospital cost was €8,900 ranging from €157 to €279,600. 56% of this cost was due to acute care, 38% to rehabilitation care and 6% to home stays.

Conclusions: Studying hospitalization data for SMA patients in France provides a better understanding of the economic burden of SMA. If acute care is at the heart of the patient management, the economic burden is balanced between acute care and rehabilitation care.

Access full article